Article

Let's talk about sex

Author(s):

Jon Garinn blog image

Sex is one topic that always seems to generate interest, even at a cancer research conference. Among the many studies presented at this year's annual meeting of the American Society of Clinical Oncology: a first-of-its-kind examination of spouses or long-term partners of patients with HPV-positive oropharyngeal cancers, which are located at the tongue, tonsils, pharynx and soft palate. Gypsyamber D'Souza, an associate professor of epidemiology at Johns Hopkins University in Baltimore and the study's lead author, says fear of transmitting the virus can cause couples anxiety, resulting in reduced sexual intimacy and even divorce. She and her colleagues set out to learn whether sexual partners were at increased risk of infection from the human papilloma virus and if they needed to change their sexual behaviors.The study found that the spouses or partners of patients with HPV-positive oral cancers were no more at risk of developing the disease than the general population.Taking oral rinse samples from 166 participants with HPV-positive oral cancer and 94 of their spouses or partners, the researchers tested the samples for HPV DNA. After one year, samples were again taken and tested. The prevalence of HPV infection among partners (6.5 percent) was comparable to the general population. Nearly all sexually active people will be infected with at least one type of HPV in their lifetime, even if they have only one sexual partner. The majority of infections do not develop into cancer, and most people exposed to the virus manage to "clear it," according to D'Souza.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Waldenstrom macroglobulinemia is often slow growing, with high survival but lower quality of life over time, explained researcher Alisha Kimble.
Image of woman.
Image of two doctors and text.
Combining JNJ-1900 with Keytruda may improve distant control of lung cancer, explained by Dr. Jared Weiss.
image of serzan.
Dr. Breelyn Wilky explains that personalized treatments are helping improve outcomes for patients with gastrointestinal stromal tumors.
Image of two doctors with text.
Image of doctors with text.
Imiage of two doctors with text.
Treatment with zanzalintinib plus Opdivo and Opdualag is an option worth exploring in patients with previously untreated clear cell renal cell carcinoma
Related Content